89981-03-3

Basic information

• Product Name: methyl 4-bromo-2-methylphenyl sulphide
• Synonyms: methyl 4-bromo-2-methylphenyl sulphide;4-Bromo-2-methyl-1-(methylsulfanyl)benzene
• CAS NO: 89981-03-3
• Molecular Formula: C₈H₉BrS
• Molecular Weight: 217.12606
• Mol File: 89981-03-3.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: methyl 4-bromo-2-methylphenyl sulphide(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 4-bromo-2-methylphenyl sulphide(89981-03-3)
• EPA Substance Registry System: methyl 4-bromo-2-methylphenyl sulphide(89981-03-3)

Safety Data

• Hazardous Substances Data: 89981-03-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Methyl 4-bromo-2-methylphenyl sulphide is used as a building block for the synthesis of pharmaceutical compounds due to its unique chemical structure and properties.
Used in Agrochemical Industry:
Methyl 4-bromo-2-methylphenyl sulphide is used as a building block for the synthesis of agrochemical compounds, contributing to the development of new pesticides and other agricultural products.

Upstream product

• 14092-00-3 methyl o-tolyl sulfide 

Downstream Products

• 99768-21-5 4-bromo-2-methyl-1-(methylsulfonyl)benzene 
• 851669-34-6 3-methyl-4-(methylthio)benzoic acid 
• 99-04-7 m-Toluic acid 

Relevant articles and documents

Ligand-free Ni-catalyzed reductive cleavage of inert carbon - Sulfur bonds

A catalytic reductive cleavage of C(sp2) - and C(sp3) - SMe bonds under ligandless conditions is presented. The method is characterized by its wide scope and high chemoselectivity profile including challenging substrate combinations, allowing the design of orthogonal and site-selectivity approaches.

1,1-(Dimethyl-Ethylamino)-2-Hydroxy-Propoxy]-Ethyl}-3-Methyl-Biphenyl-4- Carboxylic Acid Derivatives As Calcium Receptor Antagonists

The present invention is directed to novel 1,1 -(dimethyl-ethylamino)-2- hydroxy-propoxy]-ethyl}-3-methyl-biphenyl-4-carboxylic acid derivatives and pharmaceutically acceptable salts thereof of structural formula I wherein the variable R1 is as described herein. Also provided are pharmaceutical compositions comprising the compounds of formula I as well as methods of treatment employing compounds of formula I to treat a disease or disorder characterized by abnormal bone or mineral homeostasis such as hypoparathyroidism, osteoporosis, osteopenia, periodontal disease, Paget's disease, bone fracture, osteoarthritis, rheumatoid arthritis, and humoral hypercalcemia of malignancy.